Shares of Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) crossed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of C$0.01 and traded as low as C$0.01. Aequus Pharmaceuticals shares last traded at C$0.01, with a volume of 100,000 shares trading hands.
Aequus Pharmaceuticals Stock Down 37.5%
The company has a debt-to-equity ratio of 138.88, a current ratio of 0.07 and a quick ratio of 0.46. The stock has a 50 day simple moving average of C$0.01 and a 200-day simple moving average of C$0.01. The firm has a market cap of C$663,150.00, a PE ratio of -0.50 and a beta of -0.02.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.
Featured Articles
- Five stocks we like better than Aequus Pharmaceuticals
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
